middle.news
How Imagion Biosystems Is Revolutionizing HER2 Breast Cancer Imaging Ahead of Phase 2 Trial
9:55am on Tuesday 7th of October, 2025 AEDT
•
Healthcare
Read Story
How Imagion Biosystems Is Revolutionizing HER2 Breast Cancer Imaging Ahead of Phase 2 Trial
9:55am on Tuesday 7th of October, 2025 AEDT
Key Points
Manufacturing of MagSense® HER2 imaging agent completed for Phase 2 trial
Collaboration with Siemens and Wayne State University advancing AI imaging protocol optimization
AU$3.5 million capital raise secured to fund IND submission and clinical trial
IND application submission on track for second half of 2025 despite US government shutdown
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Imagion Biosystems (ASX:IBX)
OPEN ARTICLE